Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy InVivo Therapeutics stock (NVIV)

Buy InVivo Therapeutics stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

InVivo Therapeutics is a biotechnology business based in the US. InVivo Therapeutics shares (NVIV) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.32 – the same closing value as a week prior. InVivo Therapeutics employs 6 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy InVivo Therapeutics stock

Top pick for advanced traders

Go to site
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

Our pick for transfer bonus

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • Complimentary access to a financial planner and automated investing

How to buy InVivo Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – NVIV. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy InVivo Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
OPTO
Finder Score: 3.1 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Zero-commission stocks, ETFs and options, with no options per-contract fees. Plus, a no-advisory-fee robo-advisor and complimentary access to financial planners.
Robinhood
Finder Score: 4.5 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

InVivo Therapeutics stock price (NASDAQ: NVIV)

Use our graph to track the performance of NVIV stocks over time.

InVivo Therapeutics shares at a glance

Information last updated 2024-04-07.
Latest market close$0.32
52-week range$0.22 - $1.05
50-day moving average $0.61
200-day moving average $0.99
Wall St. target price$37.50
PE ratio N/A
Dividend yield N/A
Earnings per share (TTM) $-3.28

Is it a good time to buy InVivo Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

InVivo Therapeutics price performance over time

Historical closes compared with the close of $0.3207 from 2024-02-12

1 week (2024-10-18) N/A
1 month (2024-09-25) N/A
3 months (2024-07-25) N/A
6 months (2024-04-25) N/A
1 year (2023-10-27) -65.52%
2 years (2022-10-28) -86.24%
3 years (2021-10-29) 0.58
5 years (2019-10-29) 14.4

InVivo Therapeutics financials

Gross profit TTM $0
Return on assets TTM -53.71%
Return on equity TTM -98.11%
Profit margin 0%
Book value $2.87
Market Capitalization $995,917

TTM: trailing 12 months

InVivo Therapeutics share dividends

We're not expecting InVivo Therapeutics to pay a dividend over the next 12 months.

Have InVivo Therapeutics's shares ever split?

InVivo Therapeutics's shares were split on a 1:25 basis on 26 April 2022 . So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your InVivo Therapeutics shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for InVivo Therapeutics shares which in turn could have impacted InVivo Therapeutics's share price.

InVivo Therapeutics share price volatility

Over the last 12 months, InVivo Therapeutics's shares have ranged in value from as little as $0.222 up to $1.05. A popular way to gauge a stock's volatility is its "beta".

NVIV.US volatility(beta: 0.66)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while InVivo Therapeutics's is 0.658. This would suggest that InVivo Therapeutics's shares are less volatile than average (for this exchange).

InVivo Therapeutics overview

InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.

Frequently asked questions

What percentage of InVivo Therapeutics is owned by insiders or institutions?
Currently 0.021% of InVivo Therapeutics shares are held by insiders and 3.444% by institutions.
How many people work for InVivo Therapeutics?
Latest data suggests 6 work at InVivo Therapeutics.
When does the fiscal year end for InVivo Therapeutics?
InVivo Therapeutics's fiscal year ends in December.
Where is InVivo Therapeutics based?
InVivo Therapeutics's address is: One Kendall Square, Cambridge, MA, United States, 02139
What is InVivo Therapeutics's ISIN number?
InVivo Therapeutics's international securities identification number is: US46186M6057
What is InVivo Therapeutics's CUSIP number?
InVivo Therapeutics's Committee on Uniform Securities Identification Procedures number is: 46186M506

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site